ai-medical-device
(3)
Nervio
Nervio is an Israeli-American digital health company building AIM, an AI-powered intraoperative neuromonitoring (IONM) system that turns raw surgical signal data into real-time alerts and recommendations. Founded in 2020 by brothers Dr. Omer Zarchi and Nir Zarchi, the company aims to prevent avoidable paralysis and nerve injury during spine and neurosurgery at a time when the number of surgeries is climbing and the pool of expert neurophysiologists is shrinking. Nervio operates from Nashville, Tennessee with an R&D center in Israel, and its technology has been developed with input from dozens of neurophysiologists across more than 1,000 surgical cases.
DermaSensor, Inc.
DermaSensor is a Miami-based medical device company that makes the first FDA-cleared, AI-powered handheld device for detecting all three common skin cancers - melanoma, basal cell carcinoma, and squamous cell carcinoma - at the point of care. Using elastic scattering spectroscopy and a machine learning algorithm trained on thousands of biopsy-confirmed lesions, the device gives primary care physicians a real-time, non-invasive read on whether a suspicious skin lesion warrants further evaluation, helping close the gap created by a shortage of dermatologists.
Cody Simmons
Cody Simmons is the co-founder and CEO of DermaSensor, a Miami-based medical device company behind the first FDA-cleared, AI-powered handheld tool that helps primary care physicians evaluate skin lesions for cancer in seconds using elastic scattering spectroscopy. A bioengineer with a Brown degree, a Stanford master's and four years at Genentech, he took over the company in 2016 and spent nearly a decade shrinking a microwave-sized prototype into a point-and-click device, navigating FDA breakthrough designation, a De Novo clearance in early 2024, and a $16M Series B in 2025.